Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Magnetic Resonance Spectroscopy 262Specimen Handling 253pembrolizumab 230Cyclophosphamide 216Radiotherapy 204Nivolumab 168Cisplatin 161Carboplatin 145Biopsy 144Radiosurgery 128fludarabine 123Blood Specimen Collection 116Gemcitabine 111Paclitaxel 107Surveys and Questionnaires 106Standard of Care 102venetoclax 94Dexamethasone 93Bevacizumab 92Radiation 87Rituximab 81Capecitabine 80Cytarabine 79Oxaliplatin 77Drug Therapy 75Doxorubicin 75Ipilimumab 73durvalumab 70fludarabine phosphate 69atezolizumab 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × lorukafusp alfa × 90 days × Clear all
NCT03958383 2026-06-03

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

University of Wisconsin, Madison

Phase 1/2 Terminated
8 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡